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Abstract
Aim To develop a cost-effectiveness model to compare Type 2 diabetes prevention programmes that target different at-
risk population subgroups through lifestyle interventions of varying intensity.
Methods An individual patient simulation model simulated the development of diabetes in a representative sample of
adults without diabetes from the UK population. The model incorporates trajectories for HbA1c, 2-h glucose, fasting
plasma glucose, BMI, systolic blood pressure, total cholesterol and HDL cholesterol. In the model, patients can be
diagnosed with diabetes, cardiovascular disease, microvascular complications of diabetes, cancer, osteoarthritis and
depression, or can die. The model collects costs and utilities over a lifetime horizon. The perspective is the UK National
Health Service and Personal Social Services. We used the model to evaluate the population-wide impact of targeting a
lifestyle intervention of varying intensity to six population subgroups defined as at high risk for diabetes.
Results The intervention produces 0.0020 to 0.0026 incremental quality-adjusted life-years and saves £15 to £23 per
person in the general population, depending on the subgroup targeted. Cost-effectiveness increases with intervention
intensity. The most cost-effective options were to target South-Asian people and those with HbA1c levels > 42 mmol/mol
(6%).
Conclusion The model indicates that diabetes prevention interventions are likely to be cost-saving. The criteria for
selecting at-risk individuals differentially has an impact on diabetes and cardiovascular disease outcomes, and on the
timing of costs and benefits. The model is not currently able to account for potential differential uptake or efficacy
between subgroups. These findings have implications for deciding who should be targeted for diabetes prevention
interventions.
Diabet. Med. 00, 000–000 (2015)
Introduction
In the UK, there are 3.2 million people with diabetes [1]. The
prevalence of diabetes is increasing with growing levels of
obesity and an aging population. Lifestyle interventions
targeted at those individuals known to be at higher risk of
Type 2 diabetes have been shown to be effective in reducing
its incidence [2]. There are many factors that influence an
individual’s risk of Type 2 diabetes including obesity, age,
physical activity and a family history of Type 2 diabetes.
People from certain communities and population groups are
at higher risk, including people of South-Asian, African-
Caribbean, black African and Chinese descent and those
from lower socio-economic groups. Public health guidelines
recommend lifestyle interventions for individuals at high risk
of diabetes, and communities at high risk [3,4], and a
national diabetes prevention programme is currently under
development in England [5].
Interventions targeting alternative at-risk groups are con-
sidered to be cost-effective based on economic evaluations
[3,4,6]; however, because of differences in the model
structures used, it has not been possible to compare their
relative cost-effectiveness. A recent review of economic
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evaluations for diabetes prevention interventions identified
that, in order to compare prevention interventions within a
common framework, it is necessary to incorporate multiple
risk factors for diabetes, diabetes-related complications and
obesity-related comorbidity outcomes [7].
The aim of the present study was to evaluate whether
pragmatic diabetes prevention programmes of varying inten-
sity have differential effects when targeted to alternative at-
risk groups within the population through the use of a
flexible new economic model.
Methods
School for Public Health Research diabetes prevention model
The School for Public Health Research (SPHR) diabetes
model is a micro-simulation model with a lifetime horizon
that was developed to forecast long-term health outcomes
and healthcare costs for the evaluation of diabetes prevention
strategies. The model was developed according to a new
conceptual modelling framework to guide modellers when
constructing complex public health models [8]. Given
the complexity of this model, a detailed description of the
methods and assumptions are provided in File S1 and the
variables included can be found in File S2.
The model incorporates individual-level trajectories for
BMI, HbA1c, 2-h glucose, fasting plasma glucose, systolic
blood pressure, total cholesterol and HDL cholesterol. The
trajectories are based on statistical analysis of the Whitehall
II cohort (File S1). The model was designed to simulate a
representative sample of the UK population, by using
individuals from survey data from the 2011 Health Survey
for England [9]. Individuals aged < 16 years and those with a
prior diagnosis of diabetes were excluded, leaving a popu-
lation of 8038, from which individuals were sampled at
random. The characteristics of this population and missing
data imputation methods are described in File S1. Figure 1
shows the sequence of updating clinical characteristics and
clinical events (see File S1 for a description). This sequence
was repeated for every annual cycle of the model.
Detection of diabetes, hypertension and cardiovascular
risk
In any model cycle, individuals with one or more visit to a
general practitioner may receive an opportunistic diagnosis
of diabetes, hypertension or statin eligibility. The trajectory
for glycaemia, systolic blood pressure and cholesterol
changes after treatment initiation. When an individual is
diagnosed with Type 2 diabetes after two consecutive
HbA1c test results of > 47.5 mmol/mol (6.5%) the model
simulates subsequent HbA1c test results using the UK
Prospective Diabetes Study (UKPDS) outcomes model [10].
Furthermore, if an individual is prescribed antihypertensive
treatment or statins in line with national guidelines
[11,12], their systolic blood pressure or total cholesterol
is reduced in line with changes observed in randomized
controlled trials [13,14] and held constant for all subse-
quent cycles. The frequency of visits to a general practi-
tioner was estimated from data from the South Yorkshire
cohort, adjusted for individual characteristics. Details of
the study population and the method used to simulate
general practice attendance are described in File S1.
Long-term health outcomes
The model simulates a number of health outcomes that are
related to BMI and diabetes. Further details of how these
conditions were diagnosed and all other health outcomes are
provided in File S1. The QRISK2 algorithm was used to
estimate the probability of a cardiovascular disease (CVD)
event [15]. CVD events were allocated to either stable
angina, unstable angina, myocardial infarction, transient
ischaemic attack, stroke, death from coronary heart disease
or vascular disease, according to probability distributions
used in a previous Health Technology Assessment [16]. This
source was also used to estimate subsequent CVD events if
the first event was not fatal.
The probability of congestive heart failure was estimated
using the Framingham Heart Study congestive heart disease
risk model for men and women [17]. Microvascular events
including renal failure, blindness, foot ulcer and amputa-
tion were simulated using the UKPDS outcomes models
[10,18].
Breast and colorectal cancer incidence [19,20] was esti-
mated from analysis of the EPIC-Norfolk cohort. The
association between BMI and cancer was obtained from a
large meta-analysis of prospective observational studies [21].
UK mortality statistics determined the risk of mortality after
breast or colorectal cancer [22]. Osteoarthritis incidence and
association with BMI and HbA1c ≥ 48 mmol/mol (6.5%)
What’s new?
• We describe the first study to compare the cost-
effectiveness of a lifestyle intervention, designed to
prevent diabetes, across different high-risk population
subgroups and different intervention intensities.
• We found that diabetes prevention programmes are
potentially cost-saving over a lifetime horizon, regard-
less of risk criteria or intervention intensity.
• Our study estimates that a lifestyle intervention will
have a differential impact on disease outcomes (diabetes
vs. cardiovascular disease) and time horizon of cost
savings in different high-risk groups.
• These findings should help policy-makers decide their
objectives in developing suitable criteria for diabetes
prevention programme content and eligibility.
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was estimated from analysis of an Italian observational
cohort [23]. The incidence of depression in individuals
without diabetes was obtained from a US cohort [24]. The
risk of depression was inflated upon diagnosis of diabetes
[24] and stroke [25].
Other-cause mortality describes the risk of death from any
cause except CVD and cancer. Mortality rates by age and sex
were extracted from the Office of National Statistics,
excluding deaths from CVD, breast cancer, colorectal cancer
and diabetes [26]. An increased risk of mortality was
assigned to individuals with diabetes using data from a
published meta-analysis [27].
Estimating costs and quality-adjusted life-years
Costs were estimated from a National Health Service and
Personal Social Services perspective in 2012–2013 UK
pounds sterling. Costs were assigned to the health outcomes
simulated in the model to estimate an overall cost for each
individual in the model.
Diabetes_Dx=1
Hypertenson=0
Cancer history=1Cancer history=0
Depression=0
2. GP visits.
3. BMI.
4.a. Glucose.
Diabetes_Dx=0
1. Age
4.a. HbA1c+treatment.
5.a. Blood pressure. 5.b. Blood pressure.
Hypertenson=1
6.a. Cholesterol 6.a. Cholesterol
Stan=0 Stan=1
7. Screening.
8.a. CVD events 8.b. CVD events 
CVD history=0 CVD history=1
9. CVD 
Mortality
10. Renal failure, ulcer, 
amputaon and blind
HbA<6.5
HBA>6.5
11.a. Cancer events 11.b. Cancer events 11.b. Cancer Mortality
Osteohistory=1Osteohistory=0
12. Osteoevents
13. Depression
Depression=1
14. All cause 
mortality
FIGURE 1 School for Public Health Research model schematic. Please see supplementary file 1 for a detailed description of the model schematic and
how a hypothetical patient progresses through the model. CVD, cardiovascular disease; GP, general practice.
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At baseline, EQ-5D questionnaire scores were extracted
from the Health Survey for England (HSE) dataset to describe
an individual’s health-related quality of life. A utility
decrement for age was applied to the baseline EQ-5D score
each year [16]. Change in BMI was also associated with a
quality-of-life decrement [6]. CVD, cancer, microvascular
disease osteoarthritis and depression were associated with a
utility factor decrement which was multiplied by the
individual’s utility, adjusted for age and change in BMI.
Costs and quality-adjusted life-years (QALYs) were dis-
counted by 1.5% in line with the UK guidelines for public
health interventions [28]. Details of how costs and utilities
were estimated and how they were used in the model are
given in File S1.
High-risk subgroups
We selected six sets of criteria to identify alternative
subgroups of individuals at high risk of diabetes within the
UK general population. The at-risk groups included individ-
uals of South-Asian ethnicity, individuals in the lowest
quintile of deprivation (low socio-economic status), individ-
uals with HbA1c > 42 mmol/mol (6%), individuals with BMI
> 35 kg/m2, individuals aged 40–65 years, and individuals
with a Finnish Diabetes Risk (FINDRISC) 10 year prob-
ability score > 0.1 [29]. Summary characteristics for the six
groups and the general population are reported in Table 1.
To enable fair comparison between the six scenarios, we
assumed that there was a budget constraint meaning that
only 2% of the total adult population could be enrolled in
the intervention.
Intervention
The effectiveness of the intervention was based on a recent
meta-analysis of diabetes prevention programmes promoting
dietary and/or physical activity lifestyle changes [2]. The
review identified mean changes in BMI, HbA1c, systolic
blood pressure and total cholesterol. To make these changes
conditional on baseline values, we estimated the percentage
change over 12 months. The effects of the intervention were
applied in the first year of the model to all enrolled
individuals and were assumed to deteriorate over 5 years
until the individual returned to their natural growth rate for
metabolic risk factors, consistent with previous National
Institute for Health and Care Excellence (NICE) evaluations
[30].
The meta-analysis of diabetes prevention interventions [2]
reported a gradient of effect on weight change and BMI
according to adherence of the studies to prevention pro-
gramme guidelines. We used this analysis to evaluate trade-
offs between the investment in an intervention against its
intensity (intensity is defined in broad terms of adherence to
the guidelines). The default setting for our model was to
evaluate a moderate intensity intervention, which was
equivalent to the mean change in the meta-analysis. As
alternative analyses, we examined the cost-effectiveness of
low- and high-intensity interventions. The effectiveness data
for these was based on assuming that either four fewer or
four more NICE guidelines were followed during interven-
tion implementation, given that adherence to NICE guide-
lines has been linked to increased weight loss at 12 months
[2]. Direct effects on glycaemia, systolic blood pressure and
total cholesterol were assumed to vary in line with the
measured effects on BMI. The costs of low-, medium- and
high-intensity interventions were an assumption based on
intervention costs estimated in NICE public health guidance
PH38 [30], and are shown in Table 2, together with
effectiveness data.
Outcomes
We estimated the incremental costs and incremental
QALYs generated by the intervention compared with the
‘do-nothing’ control, averaged across the whole adult
general population simulated, rather than just the inter-
Table 1 Summary of subpopulation characteristics
General UK
population
Age 40–65
years
Low socio-
economic
status
HbA1c > 42
mmol/mol
(6%)
Finnish Diabetes
Risk probability
score > 0.1
BMI ≥ 35
kg/m2
South-
Asian
Total population, % 100 48 18 15 12 8 4
Male, % 44 44 44 45 40 34 42
White, % 90 92 80 92 96 91 0
Low socio-economic status, % 18 15 100 16 16 24 37
Mean (SD) age 48.6 (18.4) 54.1 (8.4) 44.7 (8.2) 61.2 (16.0) 66.3 (14.0) 50.0 (16.0) 38.3 (13.6)
Mean (SD) BMI, kg/m2 27.2 (5.4) 27.9 (5.3) 27.4 (5.9) 28.7 (5.5) 34.21 (4.0) 39.0 (4.0) 26.6 (5.3)
Mean (SD) HbA1c, mmol/mol 38 39 38 44 41 39 32
Mean (SD) HbA1c, % 5.6 (0.5) 5.7 (0.4) 5.6 (0.5) 6.2 (0.1) 5.9 (0.5) 5.7 (0.6) 5.1 (0.5)
Mean (SD) systolic blood pressure,
mmHg
125 (17.1) 128 (16.5) 125 (17.0) 133 (17.3) 135 (17.0) 128 (16.9) 120 (15.5)
Mean (SD) total cholesterol, mmol/l 5.4 (1.1) 5.7 (1.0) 5.3 (1.1) 5.8 (1.0) 5.8 (1.0) 5.5 (1.0) 5.2 (1.1)
Mean (SD) HDL cholesterol, mmol/l 1.5 (0.4) 1.6 (0.5) 1.5 (0.4) 1.5 (0.5) 1.5 (0.4) 1.5 (0.4) 1.4 (0.4)
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vention beneficiaries. As the intervention was cost-saving in
every analysis, incremental cost-effectiveness ratios were
negative. To overcome the problems with ranking negative
incremental cost-effectiveness ratios, we estimated the
overall incremental monetary benefit of the interventions
per person by assuming a willingness to pay (k) of £20,000
per QALY. Net benefit values above zero are cost-effective,
with higher values being more cost-effective than lower
values.
incremental net benefit ¼ kðincremental QALYÞ
 ðincremental costÞ
The model also allowed us to estimate the incremental
change in diabetes and CVD diagnoses. Outcomes were
collected after 1 year, 5 years, 10 years and lifetime to
estimate the timings of cost-savings. To investigate param-
eter uncertainty, 1000 probabilistic sensitivity analysis sam-
ples were run for a total population of 20 000 individuals for
the default moderate intensity intervention targeting all
population subgroups (File S3). Deterministic analysis using
one million individuals was used to obtain results for all
three intervention intensities, together with a series of one-
way sensitivity analyses. A full list of sensitivity analyses/
assumptions tested is reported in File S4.
Results
The estimated incremental cost-effectiveness results for the
deterministic analysis are reported in Table 3. All three
intervention intensities increase QALYs and are cost-saving
over the lifetime of the population, compared with doing
nothing. High-intensity interventions are more cost-effec-
tive than interventions of moderate or low intensity.
Table 2 Effectiveness of hypothetical prevention intervention
Low
intensity
Medium
intensity
High
intensity
% change in BMI from
baseline
1.3 3.0 4.7
% change in Hba1c
from baseline
1.0 2.2 3.4
% change in systolic blood
pressure from baseline
1.9 4.3% 6.7
% change in total
cholesterol from baseline
1.5 3.4 5.3
Intervention cost £43 £100 £157
Follow-up cost £26 £60 £94
Table 3 Incremental simulated outcomes for one million individuals in the general population (adult 16-99) over a lifetime perspective
Targeting strategy
Adults aged
40–65 years
Low socio-
economic status
HbA1c > 42
mmol/mol (6%)
Finnish Diabetes
Risk probability
score > 0.1 BMI > 35 kg/m2 South-Asian
A: Incremental net benefit (per person)
Low intensity £29 £32 £35 £26 £31 £31
Medium intensity £62 £73 £74 £55 £66 £74
High intensity £92 £103 £107 £80 £101 £108
B: Incremental total discounted costs (per person)
Low intensity £8 £9 £12 £7 £13 £9
Medium intensity £17 £21 £23 £15 £23 £22
High intensity £23 £30 £34 £20 £36 £32
C: Incremental total discounted QALYs (per person)
Low intensity 0.0010 0.0012 0.0011 0.0010 0.0009 0.0011
Medium intensity 0.0022 0.0026 0.0025 0.0020 0.0021 0.0026
High intensity 0.0034 0.0037 0.0036 0.0030 0.0033 0.0038
D: Incremental life-years
Low intensity 1658 1912 1562 1659 1687 1796
Medium intensity 3417 4546 3683 3468 3875 4456
High intensity 5329 6716 5560 5007 5901 6445
E: Incremental cost-effectiveness ratios (£ per QALY)
Low intensity £8,388 £7,694 £10,823 £7,646 £13,948 £8,217
Medium intensity £7,692 £8,230 £9,136 £7,143 £10,803 £8,385
High intensity £6,761 £8,026 £9,281 £6,806 £10,954 £8,274
F: Incremental diabetes diagnosis
Low intensity 37 36 111 100 49 1
Medium intensity 97 62 229 201 127 5
High intensity 121 83 336 304 197 15
G: Incremental cardiovascular disease events
Low intensity 217 223 220 190 238 188
Medium intensity 497 493 457 421 519 478
High intensity 756 736 676 641 754 716
QALY, quality-adjusted life-years.
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Comparisons between subgroups indicate large variations
in lifetime costs, QALYs and net benefits accrue for differ-
ent subpopulations. Targeting interventions to South-Asian
people, individuals with HbA1c > 42 mmol/mol (6%) or
individuals from low socio-economic backgrounds are the
most cost-effective options. Targeting individuals with a
high FINDRISC score is less cost-effective than any other
option.
Table 4 reports the incremental costs at 1 year, 5 years
and 10 years to describe how the initial intervention invest-
ment is reduced over time as a result of cost savings.
Interventions for individuals identified by FINDRISC prob-
ability score > 0.1 or HbA1c > 42 mmol/mol (6%) have the
greatest cost savings after 1–10 years. Low socio-economic
status and South-Asian groups take longer to recover costs
despite generating high lifetime cost savings. This show that
the interventions which are most likely to accrue the highest
net benefit over a lifetime are not necessarily the most cost-
saving in the short term.
There are important differences between the subgroups in
how health benefits are distributed in terms of disease events.
Interventions in adults aged 40–65 years, South-Asians and
those with low socio-economic status have a large impact in
reducing CVD, but have less effect, if any, in reducing lifetime
diabetes. By contrast, intervening in individuals identified by
a FINDRISC probability score > 0.1 or HbA1c > 42 mmol/
mol (6%) has a large impact in reducing diabetes diagnosis,
but is slightly less effective in reducing CVD events.
Results from the probabilistic sensitivity analyses indicate
that the intervention is highly likely to save costs and gain
QALYs in all six subgroups, as the vast majority of
probabilistic sensitivity analysis results are located in the
south-east quadrant of the cost-effectiveness plane (Fig. 2
and File S3). Probabilistic sensitivity analysis results differ
slightly from deterministic results because of the non-
linearity of the model. Cost-effectiveness acceptability curves
indicate that no individual subgroup has a particularly high
probability of using resources most cost-effectively, but that
the intervention is very unlikely to be more cost-effective to
implement in individuals with a high FINDRISC score than
in other subgroups (Fig. 2). Uncertainty around the cost-
effectiveness of alternative subgroups is stable over different
willingness-to-pay thresholds.
Finally, the intervention remains cost-effective in all
population subgroups in all deterministic sensitivity analyses,
and in most cases the South-Asian or HbA1c > 42 mmol/mol
(6%) subgroups remain the most cost-effective. A detailed
description of the results from the sensitivity analysis can be
found in File S4.
Discussion
The analysis has shown that there are potentially substan-
tial gains in health and cost savings available from diabetes
prevention interventions, regardless of population target or Ta
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intensity. The new SPHR diabetes prevention model was
developed so that diabetes prevention interventions with
different weight change outcomes can be flexibly specified
to target alternative populations reflecting multiple risk
factors for diabetes and CVD. The analysis highlights that
population heterogeneity will affect the cost-effectiveness of
public health interventions. We found that applying the
same intervention in different high-risk groups produces
very different cost savings and QALY gains, events avoided
and timings for the cost savings.
Targeting South-Asian populations generates the greatest
overall lifetime net benefit because of the importance of
preventing CVD, but actually increases the lifetime incidence
of Type 2 diabetes. This counterintuitive result can be
explained by individuals surviving CVD and living longer,
thereby having more time to develop diabetes later in life.
Cost savings are slow to accrue in this group (as in the group
with low socio-economic status) because of the relative youth
of individuals at the model start. Conversely, an HbA1c
concentration > 42 mmol/mol (6%) and a FINDRISC
probability score > 0.1 are the most effective subgroups to
target to reduce diabetes diagnoses, and generate the greatest
short-term cost savings, although targeting individuals with
HbA1c > 42 mmol/mol (6%) is a much more cost-effective
strategy than targeting those with FINDRISC probability
score > 0.1.
The analysis described in the present paper is limited by an
absence of evidence. In particular, we were not able to obtain
estimates of how intervention effect sizes or intervention
costs might vary by subgroup (e.g. through ease of recruit-
ment), which limits our ability to make recommendations
about which individuals should be targeted. Further research
involving subgroup analysis would be extremely useful to
inform this variable. More generally, the analysis assumed
that the reduction in metabolic trajectories after intervention
was proportionate to the individual’s baseline values;
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however, in reality, individuals will vary hugely in their
response to intervention, and individuals with very low risk
factors may not experience the same proportionate reduc-
tion. Finally, we based the model on diagnosis of individuals
through HbA1c, but other diagnostic methods (e.g. fasting
plasma glucose) will identify a different subset of individuals
with diabetes [31]; however, we think this is unlikely to
significantly alter the results at the population level.
Two previous UK-based economic evaluations have found
lifestyle interventions for diabetes prevention are cost-effec-
tive but not cost-saving in subgroups with either low socio-
economic status or high diabetes risk score and HbA1c
> 42 mmol/mol (6%) [3,4]. There are a number of factors
that we believe can explain the differences. Firstly, the SPHR
model includes a broader range of health outcomes such as
depression, osteoarthritis, breast and colorectal cancer that
were not included in previous evaluations. Secondly, the
costs of major events, such as cardiovascular disease have
increased as a result of inflation. Thirdly, the cost of
screening individuals for Type 2 diabetes in order to identify
individuals at high risk because of hyperglycaemia was not
included in the SPHR model.
In the present analysis, we investigated six high risk groups
separately, but it is highly likely that combining criteria could
optimize resource allocation to a subpopulation with even
greater gains in health and cost savings. The SPHR model
can be easily modified to evaluate combined treatment
criteria, in addition to a variety of alternative policies for
Type 2 diabetes prevention. UK policy-makers can use this
model to decide which populations they wish to target with
lifestyle interventions according to their overall objectives,
whether short- or long-term gains, equity or efficiency, or
preventing CVD or diabetes.
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